{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:46:51Z","timestamp":1790801211738,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30973931\/81673678"],"award-info":[{"award-number":["30973931\/81673678"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jpba.2024.116473","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T06:58:40Z","timestamp":1726124320000},"page":"116473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pharmacovigilance of drug-drug interactions: A pharmacokinetic study on the combined oral administration of lurasidone and clozapine in rats by using LC-MS\/MS"],"prefix":"10.1016","volume":"252","author":[{"given":"Orwa","family":"Siddig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-jun","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpba.2024.116473_bib1","first-page":"120","article-title":"A current review of cytochrome p450 interactions of psychotropic drugs","volume":"26","author":"Madhusoodanan","year":"2014","journal-title":"Ann. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jpba.2024.116473_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/17425255.2012.660918","article-title":"Interactions between antiepileptics and second-generation antipsychotics","volume":"8","author":"de Leon","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.jpba.2024.116473_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.jpba.2024.116473_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ddr.21337","article-title":"Improving current treatments for schizophrenia","volume":"77","author":"Maric","year":"2016","journal-title":"Drug Dev. Res."},{"issue":"2","key":"10.1016\/j.jpba.2024.116473_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199324020-00005","article-title":"Pharmacokinetics and pharmacodynamics of clozapine","volume":"24","author":"Jann","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116473_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","article-title":"Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature","volume":"56","author":"Greenberg","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.jpba.2024.116473_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041072","article-title":"Clozapine in treatment-resistant schizophrenia and its augmentation with electroconvulsive therapy in ultra-treatment-resistant schizophrenia","volume":"11","author":"Peitl","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jpba.2024.116473_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S1742646413000332","article-title":"Drug interactions affecting clozapine levels","volume":"11","author":"Singh H","year":"2015","journal-title":"J. Psychiatr. Intensive Care"},{"issue":"4","key":"10.1016\/j.jpba.2024.116473_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0030-1249097","article-title":"Combination therapy in the treatment of schizophrenia","volume":"43","author":"Wolff-Menzler","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpba.2024.116473_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/NDT.S18059","article-title":"Critical appraisal of lurasidone in the management of schizophrenia","volume":"8","author":"Caccia","year":"2012","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.jpba.2024.116473_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13030445","article-title":"Lurasidone augmentation of clozapine in schizophrenia-retrospective chart review","volume":"13","author":"Siwek","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.jpba.2024.116473_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115834","article-title":"Separation and characterization of related substances of lurasidone hydrochloride by lc-qtof-ms techniques","volume":"238","author":"Siddig","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2024.116473_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/jms.4871","volume":"57","author":"Wang","year":"2022","journal-title":"J. Mass Spectrom."},{"issue":"6","key":"10.1016\/j.jpba.2024.116473_bib14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/dta.1698","article-title":"The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography-tandem mass spectrometry","volume":"7","author":"Patteet","year":"2015","journal-title":"Drug Test. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2024.116473_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/bmc.3651","article-title":"Lc-ms\/ms assay for the determination of lurasidone and its active metabolite, id-14283 in human plasma and its application to a clinical pharmacokinetic study","volume":"30","author":"Katteboina","year":"2016","journal-title":"Biomed. Chromatogr."},{"issue":"12","key":"10.1016\/j.jpba.2024.116473_bib16","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/bmc.1625","article-title":"Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry","volume":"25","author":"Koo","year":"2011","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2024.116473_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10337-012-2294-5","article-title":"A sensitive and selective LC-MS method for the determination of lurasidone in rat plasma, bile, and urine","volume":"75","author":"Chae","year":"2012","journal-title":"Chromatographia"},{"issue":"4","key":"10.1016\/j.jpba.2024.116473_bib18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.pharep.2016.04.002","article-title":"Lurasidone: the 2016 update on the pharmacology, efficacy and safety profile","volume":"68","author":"Jaeschke","year":"2016","journal-title":"Pharmacol. Rep."},{"issue":"3","key":"10.1016\/j.jpba.2024.116473_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/dmdi-2014-0005","article-title":"Lurasidone drug-drug interaction studies: a comprehensive review","volume":"29","author":"Chiu","year":"2014","journal-title":"Drug Metab. Drug Interact."},{"issue":"12","key":"10.1016\/j.jpba.2024.116473_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/bmc.1625","article-title":"Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry","volume":"25","author":"Koo","year":"2011","journal-title":"Biomed. Chromatogr."},{"issue":"3","key":"10.1016\/j.jpba.2024.116473_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/00498254.2020.1851070","article-title":"Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid","volume":"51","author":"Li","year":"2021","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.jpba.2024.116473_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00213-013-3234-2","article-title":"Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats","volume":"231","author":"Fija\u0142","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpba.2024.116473_bib23","unstructured":"ICH guideline m10 on bioanalytical method validation, EMA\/CHMP\/ICH\/172948\/2019. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline (Accessed 13 March 2019)."},{"key":"10.1016\/j.jpba.2024.116473_bib24","unstructured":"U.S. FDA Clinical drug interaction studies-cytochrome p450 enzyme-and transporter-mediated drug interactions guidance for industry; 2020. Available online 4 February 2024; Available from: https:\/\/www.fda.gov\/media\/134581\/download."},{"issue":"11","key":"10.1016\/j.jpba.2024.116473_bib25","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.clinthera.2022.09.009","article-title":"Strong pharmacokinetic drug-drug interactions with drugs approved by the US Food and Drug Administration in 2021: mechanisms and clinical implications","volume":"44","author":"Yu","year":"2022","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.jpba.2024.116473_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jpba.2024.116473_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-859X-4-1","article-title":"QT Interval Prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy","volume":"4","author":"Sala","year":"2005","journal-title":"Ann. Gen. Psychiatry"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T19:26:16Z","timestamp":1730661976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524005132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"alternative-id":["S0731708524005132"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116473","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacovigilance of drug-drug interactions: A pharmacokinetic study on the combined oral administration of lurasidone and clozapine in rats by using LC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116473"}}